Try GOLD - Free
How strategic angel investment is driving global expansion in medtech and diagnostics
BioSpectrum Asia
|December 2024
India has firmly established itself as a key player in the global medtech and diagnostics sectors. With a burgeoning healthcare ecosystem and a growing focus on innovation, the country offers a fertile ground for startups looking to scale their solutions both domestically and internationally. Central to this growth is the role of strategic angel investment, which not only provides financial backing but also offers critical mentorship and strategic direction to help these companies expand their reach.
The medtech and diagnostics sectors are among the fastest-growing industries worldwide. Factors such as an ageing global population, increasing rates of chronic diseases, and a greater focus on preventive healthcare have all fuelled the demand for advanced medical technologies and diagnostic tools. As a result, many companies are racing to develop innovative solutions that meet the needs of patients and healthcare providers.
India, with its extensive and diverse healthcare system, is poised to take advantage of these trends. The country is already home to a rapidly expanding medtech ecosystem, driven by advancements in areas like artificial intelligence, wearable medical devices, and diagnostic imaging technologies. These innovations have the potential to not only improve healthcare delivery in India but also to create scalable solutions that can be adopted worldwide. This is where strategic angel investment comes in, enabling startups to navigate the complexities of both domestic and global markets.
The Vital Role of Strategic Angel Investors
Strategic angel investors play a crucial role in the development of medtech and diagnostics companies. While they provide essential early-stage capital, their value goes far beyond financial support. These investors bring decades of experience in scaling businesses and offer mentorship that helps startups refine their strategies, products, and market positioning.
Strategic angel investors are particularly important for startups looking to expand internationally. Their extensive networks and global market knowledge allow them to provide startups with access to international markets, regulatory pathways, and distribution channels. This is invaluable for MedTech companies aiming to scale their products and reach healthcare providers across different regions.
This story is from the December 2024 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
Alphamab Oncology appoints Fei Wang as Chief Financial Officer
Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market
DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
PHCbi introduces LiCellGrow Cell Expansion System
PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences
CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala
Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation
Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Argo Biopharma ropes in Dr Gena Wang as CFO and CSO
China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust
The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Korea designs model for accurate and scalable drug-drug interaction prediction
A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.
1 min
BioSpectrum Asia April 2027
Listen
Translate
Change font size

